DK2753609T3 - Benzothiazolonforbindelse - Google Patents
Benzothiazolonforbindelse Download PDFInfo
- Publication number
- DK2753609T3 DK2753609T3 DK12770249.6T DK12770249T DK2753609T3 DK 2753609 T3 DK2753609 T3 DK 2753609T3 DK 12770249 T DK12770249 T DK 12770249T DK 2753609 T3 DK2753609 T3 DK 2753609T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- pharmaceutically acceptable
- formula
- acceptable salt
- free form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
- Emergency Medicine (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Forbindelse af formlen I på fri form eller som et farmaceutisk acceptabelt salt, som er
(I)·
2. Forbindelse ifølge krav 1, som er (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-on på fri form.
3. Forbindelse ifølge krav 1, som er (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1 -hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-on, på acetatsaltform.
4. Farmaceutisk sammensætning omfattende en terapeutisk effektiv mængde af en forbindelse ifølge ethvert af kravene 1 til 3 og ét eller flere farmaceutisk acceptable bærestoffer.
5. Farmaceutisk sammensætning ifølge krav 4, hvor ét af de farmaceutisk acceptable bærestoffer er benzylalkohol.
6. Kombination omfattende en terapeutisk effektiv mængde af en forbindelse ifølge ethvert af kravene 1 til 3 og ét eller flere terapeutisk aktive co-agenser.
7. Forbindelse ifølge ethvert af kravene 1 til 3 til anvendelse som et medikament.
8. Forbindelse ifølge ethvert af kravene 1 til 3 til anvendelse ved behandling eller forebyggelse af muskelsvindssygdomme.
9. Forbindelse til anvendelse ifølge krav 8, til behandling eller forebyggelse af
10. Fremgangsmåde til fremstilling af en forbindelse ifølge formel I på fri form eller i form af et farmaceutisk acceptabelt salt, som omfatter følgende trin: a. omsætning af en forbindelse af formlen Ila på fri form eller i form af et farmaceutisk acceptabelt salt
hvor Ra og Rb er beskyttende grupper, med 2-(4-butoxy-phenyl)-1,1-dimethylethylamin; b. fraspaltning af eventuelle beskyttende grupper, som stadig foreligger; c. isolering af den således opnåelige forbindelse af formel I på fri form eller i form af et farmaceutisk acceptabelt salt.
11. Fremgangsmåde til fremstilling af en forbindelse af formlen I på fri form eller i form af et farmaceutisk acceptabelt salt, ifølge krav 10, ved hvilken forbindelsen Ila er opnået ved omsætning af en forbindelse af formlen Illa på fri form eller i form af et farmaceutisk acceptabelt salt
hvor Ra og Rb er beskyttende grupper og LG er fraspaltelig gruppe, med en base og eventuelt en faseoverføringskatalysator.
12. Fremgangsmåde til fremstilling af en forbindelse af formlen I på fri form eller i form af et farmaceutisk acceptabelt salt, ifølge krav 11, ved hvilken forbindelsen Illa opnås ved den stereoselektive reduktion af en forbindelse af formlen IVa-2 på fri form eller i form af et farmaceutisk acceptabelt salt
(IVa-2) hvor Ra og Rb er beskyttende grupper og LG er en fraspaltelig gruppe.
13. Fremgangsmåde ifølge krav 12, hvor LG er chlor.
14. Fremgangsmåde ifølge krav 13, ved hvilken forbindelsen IVa'-2 på fri form eller i form af et farmaceutisk acceptabelt salt
(IVa'-2) opnås ved omsætning af en forbindelse af formlen Va på fri form eller i form af et farmaceutisk acceptabelt salt
(Va) hvor Ra og Rb er beskyttende grupper og Hal er et halogen, med 2-chlor-N-methoxy-N-methyl-acetamid under tilstedeværelse af en stærk base.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011079379 | 2011-09-06 | ||
| PCT/IB2012/054580 WO2013035047A1 (en) | 2011-09-06 | 2012-09-05 | Benzothiazolone compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2753609T3 true DK2753609T3 (da) | 2017-02-06 |
Family
ID=47010668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12770249.6T DK2753609T3 (da) | 2011-09-06 | 2012-09-05 | Benzothiazolonforbindelse |
Country Status (38)
| Country | Link |
|---|---|
| US (6) | US8933108B2 (da) |
| EP (1) | EP2753609B1 (da) |
| JP (2) | JP6130835B2 (da) |
| KR (2) | KR101628585B1 (da) |
| CN (2) | CN103781771B (da) |
| AP (1) | AP3830A (da) |
| AR (1) | AR087787A1 (da) |
| AU (1) | AU2013200422C1 (da) |
| BR (1) | BR112014004732A2 (da) |
| CA (1) | CA2845766A1 (da) |
| CL (1) | CL2014000493A1 (da) |
| CO (1) | CO6900147A2 (da) |
| CR (1) | CR20140114A (da) |
| CU (1) | CU24303B1 (da) |
| CY (1) | CY1118585T1 (da) |
| DK (1) | DK2753609T3 (da) |
| EA (1) | EA022909B1 (da) |
| ES (1) | ES2615052T3 (da) |
| GT (1) | GT201400042A (da) |
| HR (1) | HRP20170075T1 (da) |
| HU (1) | HUE030530T2 (da) |
| IL (1) | IL231235A (da) |
| JO (1) | JO3192B1 (da) |
| LT (1) | LT2753609T (da) |
| MX (1) | MX345405B (da) |
| MY (1) | MY163301A (da) |
| PE (1) | PE20141993A1 (da) |
| PL (1) | PL2753609T3 (da) |
| PT (1) | PT2753609T (da) |
| RS (1) | RS55468B1 (da) |
| SG (1) | SG2014013114A (da) |
| SI (1) | SI2753609T1 (da) |
| TN (1) | TN2014000060A1 (da) |
| TW (1) | TWI555738B (da) |
| UA (1) | UA114295C2 (da) |
| UY (1) | UY34312A (da) |
| WO (1) | WO2013035047A1 (da) |
| ZA (2) | ZA201401112B (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| HUE033655T2 (en) * | 2012-08-30 | 2017-12-28 | Novartis Ag | Benzothiazolone Compounds with Beta-2-Adrenoceptor Effects |
| CA2891644A1 (en) | 2012-11-19 | 2014-05-22 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
| AU2014222362B2 (en) * | 2013-02-28 | 2016-07-21 | Novartis Ag | Formulation comprising benzothiazolone compound |
| US10967119B1 (en) | 2019-04-01 | 2021-04-06 | Azizi Bilal | Wearable medication injecting device |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3855801T2 (de) * | 1987-09-15 | 1997-07-03 | Rowett Research Inst | Anwendungsgebiete von beta-adrenergenen Agonisten |
| US20070082918A1 (en) * | 1993-11-02 | 2007-04-12 | Naftchi N E | Neurologically active compounds and compounds with multiple activities |
| GB9405019D0 (en) | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| WO1999009018A1 (fr) | 1997-08-14 | 1999-02-25 | Kirin Beer Kabushiki Kaisha | DERIVES DE BENZOTHIAZOLONE PRESENTANT UNE ACTIVITE SELECTIVE D'AGONISTE DU RECEPTEUR β2 |
| CN1177831C (zh) | 1998-12-04 | 2004-12-01 | 神经研究公司 | 作为离子通道调节剂的新的苯并咪唑啉酮一、苯并噁唑酮一或苯并噻唑啉酮衍生物 |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6872723B2 (en) * | 2002-01-28 | 2005-03-29 | Wyeth | Stabilized difloxacin injectable solution |
| US6743797B2 (en) * | 2002-02-22 | 2004-06-01 | Chantest, Inc. | Methods for treating cardiac arrhythmia |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040962A1 (es) * | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| JP2006521201A (ja) * | 2003-03-26 | 2006-09-21 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 鏡像異性体富化したアルコール類およびアミン類を製造する方法 |
| AU2004226824B2 (en) * | 2003-04-04 | 2008-05-01 | Novartis Ag | Quinoline-2-one-derivatives for the treatment of airways diseases |
| JP2007503472A (ja) * | 2003-06-10 | 2007-02-22 | カリプシス・インコーポレーテッド | 病気治療用のヒストン脱アセチル化酵素阻害剤としてのカルボニル化合物 |
| EP1635800A2 (en) | 2003-06-10 | 2006-03-22 | Kalypsys, Inc. | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease |
| EP1643974A1 (en) | 2003-07-11 | 2006-04-12 | Glaxo Group Limited | Inhalable pharmaceutical formulations comprising a sugar ester |
| WO2005004852A1 (en) | 2003-07-11 | 2005-01-20 | Glaxo Group Limited | Pharmaceutical formulations |
| ES2329586T3 (es) | 2003-11-21 | 2009-11-27 | Theravance, Inc. | Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino. |
| GB0328490D0 (en) | 2003-12-09 | 2004-01-14 | Glaxo Group Ltd | Medicinal compounds |
| JP2005187357A (ja) | 2003-12-25 | 2005-07-14 | Nippon Suisan Kaisha Ltd | 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法 |
| GB0402797D0 (en) | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
| EP1595873A1 (de) | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen |
| JP2007537187A (ja) | 2004-05-13 | 2007-12-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物 |
| EP1778638A1 (en) | 2004-07-21 | 2007-05-02 | Theravance, Inc. | Diaryl ether beta2 adrenergic receptor agonists |
| DE102004045648A1 (de) | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| GB0426164D0 (en) * | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| DE102005007654A1 (de) | 2005-02-19 | 2006-08-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| TW200740781A (en) | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| WO2007086078A2 (en) | 2006-01-30 | 2007-08-02 | Panacea Biotec Ltd. | Novel pharmaceutical compositions and process of preparation thereof |
| JP5376956B2 (ja) | 2006-02-10 | 2013-12-25 | スムミト コーポレーション ピーエルシー | デュシェンヌ型筋ジストロフィーの治療 |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| GB0613154D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP2064174B1 (en) * | 2006-08-10 | 2016-10-26 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Preparation of (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure |
| TW200833670A (en) * | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| EP3251694A1 (en) | 2007-08-03 | 2017-12-06 | Summit (Oxford) Limited | Drug combinations for the treatment of duchenne muscular dystrophy |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| GB0814728D0 (en) | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| GB0823140D0 (en) | 2008-12-18 | 2009-01-28 | Astrazeneca Ab | New combination |
| GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
| GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| HUE033655T2 (en) * | 2012-08-30 | 2017-12-28 | Novartis Ag | Benzothiazolone Compounds with Beta-2-Adrenoceptor Effects |
| AU2014222362B2 (en) | 2013-02-28 | 2016-07-21 | Novartis Ag | Formulation comprising benzothiazolone compound |
-
2012
- 2012-09-04 JO JOP/2012/0250A patent/JO3192B1/ar active
- 2012-09-05 WO PCT/IB2012/054580 patent/WO2013035047A1/en active Application Filing
- 2012-09-05 PE PE2014000312A patent/PE20141993A1/es not_active Application Discontinuation
- 2012-09-05 US US13/603,990 patent/US8933108B2/en not_active Expired - Fee Related
- 2012-09-05 KR KR1020147008777A patent/KR101628585B1/ko not_active IP Right Cessation
- 2012-09-05 CA CA2845766A patent/CA2845766A1/en not_active Abandoned
- 2012-09-05 UA UAA201401193A patent/UA114295C2/uk unknown
- 2012-09-05 AP AP2014007462A patent/AP3830A/en active
- 2012-09-05 UY UY0001034312A patent/UY34312A/es not_active Application Discontinuation
- 2012-09-05 CN CN201280043386.3A patent/CN103781771B/zh not_active Expired - Fee Related
- 2012-09-05 JP JP2014529113A patent/JP6130835B2/ja not_active Expired - Fee Related
- 2012-09-05 LT LTEP12770249.6T patent/LT2753609T/lt unknown
- 2012-09-05 MX MX2014002688A patent/MX345405B/es active IP Right Grant
- 2012-09-05 TW TW101132414A patent/TWI555738B/zh not_active IP Right Cessation
- 2012-09-05 RS RS20161145A patent/RS55468B1/sr unknown
- 2012-09-05 PL PL12770249T patent/PL2753609T3/pl unknown
- 2012-09-05 SI SI201230841A patent/SI2753609T1/sl unknown
- 2012-09-05 SG SG2014013114A patent/SG2014013114A/en unknown
- 2012-09-05 BR BR112014004732A patent/BR112014004732A2/pt not_active Application Discontinuation
- 2012-09-05 EP EP12770249.6A patent/EP2753609B1/en active Active
- 2012-09-05 HU HUE12770249A patent/HUE030530T2/en unknown
- 2012-09-05 DK DK12770249.6T patent/DK2753609T3/da active
- 2012-09-05 MY MYPI2014000358A patent/MY163301A/en unknown
- 2012-09-05 PT PT127702496T patent/PT2753609T/pt unknown
- 2012-09-05 CU CUP2014000028A patent/CU24303B1/xx unknown
- 2012-09-05 CN CN201610536836.2A patent/CN106187942B/zh not_active Expired - Fee Related
- 2012-09-05 AU AU2013200422A patent/AU2013200422C1/en not_active Ceased
- 2012-09-05 EA EA201490573A patent/EA022909B1/ru not_active IP Right Cessation
- 2012-09-05 ES ES12770249.6T patent/ES2615052T3/es active Active
- 2012-09-05 KR KR1020167007782A patent/KR101800140B1/ko active IP Right Grant
- 2012-09-06 AR ARP120103276A patent/AR087787A1/es unknown
-
2014
- 2014-02-10 TN TNP2014000060A patent/TN2014000060A1/en unknown
- 2014-02-13 ZA ZA2014/01112A patent/ZA201401112B/en unknown
- 2014-02-27 CL CL2014000493A patent/CL2014000493A1/es unknown
- 2014-02-27 IL IL231235A patent/IL231235A/en active IP Right Grant
- 2014-03-04 GT GT201400042A patent/GT201400042A/es unknown
- 2014-03-06 CO CO14048375A patent/CO6900147A2/es not_active Application Discontinuation
- 2014-03-06 CR CR20140114A patent/CR20140114A/es unknown
- 2014-12-10 US US14/566,021 patent/US20150094346A1/en not_active Abandoned
-
2015
- 2015-02-03 ZA ZA2015/00790A patent/ZA201500790B/en unknown
- 2015-08-03 US US14/817,175 patent/US20150336914A1/en not_active Abandoned
- 2015-11-20 US US14/947,458 patent/US20160075670A1/en not_active Abandoned
-
2016
- 2016-06-10 US US15/178,579 patent/US9913828B2/en active Active
-
2017
- 2017-01-17 HR HRP20170075TT patent/HRP20170075T1/hr unknown
- 2017-02-02 CY CY20171100153T patent/CY1118585T1/el unknown
- 2017-03-01 JP JP2017038701A patent/JP6340103B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-22 US US15/876,619 patent/US10251868B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10251868B2 (en) | Benzothiazolone compound | |
| AU2012282107A1 (en) | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | |
| DK2961391T3 (da) | Formulering omfattende en benzothiazolonforbindelse | |
| DK2890687T3 (da) | Salte af benzothiazolonforbindelse som beta-2-adrenoceptoragonist | |
| NZ621089B2 (en) | Benzothiazolone compound |